Literature DB >> 24927658

[Radiological diagnostics of multiple myeloma].

M D'Anastasi1, S Grandl, M F Reiser, A Baur-Melnyk.   

Abstract

CLINICAL/METHODICAL ISSUE: Robust and reliable imaging methods are required to estimate the skeletal tumor load in multiple myeloma, as well as for the diagnosis of extraskeletal manifestations. Imaging also plays an essential role in the assessment of fracture risk and of vertebral fractures. STANDARD RADIOLOGICAL
METHODS: The conventional skeletal survey has been the gold standard in the imaging of multiple myeloma for many years. METHODICAL INNOVATIONS: Other modalities which have been investigated and are in use are whole-body computed tomography (WBCT), 18F-fluorodeoxyglucose positron emission tomography computed tomography (FDG PET-CT) and whole-body magnetic resonance imaging (WBMRI). These techniques are able to depict both mineralized bone and the bone marrow with a high sensitivity for myeloma lesions. PERFORMANCE: Several studies have shown that cross-sectional imaging is superior to the skeletal survey in the detection of myeloma lesions and WBMRI has been shown to be significantly more sensitive than WBCT for the detection of focal myeloma lesions as well as for diffuse infiltration. The FDG PET-CT technique has a sensitivity comparable to WBMRI. ACHIEVEMENTS: Due to the higher sensitivity in the detection of myeloma lesions WBCT and WBMRI should replace the skeletal survey. PRACTICAL RECOMMENDATIONS: A WBCT should be performed if there is suspicion of multiple myeloma. If no focal lesions are found WBMRI or at least MRI of the spine and pelvis should be additionally performed if available. If WBMRI has been initially performed and focal lesions are present, an additional WBCT may be performed to assess the extent of bone destruction and fracture risk. In cases of monoclonal gammopathy of undetermined significance (MGUS), solitary and smoldering myeloma, a WBMRI, if available, should be performed in addition to WBCT.

Entities:  

Mesh:

Year:  2014        PMID: 24927658     DOI: 10.1007/s00117-013-2628-9

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  36 in total

Review 1.  The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma.

Authors:  Jo Caers; Nadia Withofs; Jens Hillengass; Paolo Simoni; Elena Zamagni; Roland Hustinx; Yves Beguin
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

2.  Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.

Authors:  Jens Hillengass; Kerstin Fechtner; Marc-André Weber; Tobias Bäuerle; Sofia Ayyaz; Christiane Heiss; Thomas Hielscher; Thomas M Moehler; Gerlinde Egerer; Kai Neben; Anthony D Ho; Hans-Ulrich Kauczor; Stefan Delorme; Hartmut Goldschmidt
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

3.  Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates.

Authors:  A Stäbler; A Baur; R Bartl; R Munker; R Lamerz; M F Reiser
Journal:  AJR Am J Roentgenol       Date:  1996-10       Impact factor: 3.959

4.  Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Authors:  Meletios Dimopoulos; Robert Kyle; Jean-Paul Fermand; S Vincent Rajkumar; Jesus San Miguel; Asher Chanan-Khan; Heinz Ludwig; Douglas Joshua; Jayesh Mehta; Morie Gertz; Hervé Avet-Loiseau; Meral Beksaç; Kenneth C Anderson; Philippe Moreau; Seema Singhal; Hartmut Goldschmidt; Mario Boccadoro; Shaji Kumar; Sergio Giralt; Nikhil C Munshi; Sundar Jagannath
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

5.  Stage I multiple myeloma: value of MR imaging of the bone marrow in the determination of prognosis.

Authors:  B C Van de Berg; F E Lecouvet; L Michaux; M Labaisse; J Malghem; J Jamart; B E Maldague; A Ferrant; J L Michaux
Journal:  Radiology       Date:  1996-10       Impact factor: 11.105

6.  Magnetic resonance imaging of the lower vertebral column in patients with multiple myeloma.

Authors:  F X Fruehwald; D Tscholakoff; B Schwaighofer; L Wicke; A Neuhold; H Ludwig; P C Hajek
Journal:  Invest Radiol       Date:  1988-03       Impact factor: 6.016

7.  Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.

Authors:  Rosa Fonti; Michele Larobina; Silvana Del Vecchio; Serena De Luca; Rossella Fabbricini; Lucio Catalano; Fabrizio Pane; Marco Salvatore; Leonardo Pace
Journal:  J Nucl Med       Date:  2012-10-15       Impact factor: 10.057

8.  Whole-body MRI versus whole-body MDCT for staging of multiple myeloma.

Authors:  Andrea Baur-Melnyk; Sonja Buhmann; Christoph Becker; Stefan Oswald Schoenberg; Nicola Lang; Reiner Bartl; Maximilian Ferdinand Reiser
Journal:  AJR Am J Roentgenol       Date:  2008-04       Impact factor: 3.959

9.  Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging.

Authors:  Tobias Bäuerle; Jens Hillengass; Kerstin Fechtner; Christian M Zechmann; Lars Grenacher; Thomas M Moehler; Heiss Christiane; Barbara Wagner-Gund; Kai Neben; Hans-Ulrich Kauczor; Hartmut Goldschmidt; Stefan Delorme
Journal:  Radiology       Date:  2009-08       Impact factor: 11.105

10.  Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI).

Authors:  T G Gleeson; J Moriarty; C P Shortt; J P Gleeson; P Fitzpatrick; B Byrne; J McHugh; M O'Connell; P O'Gorman; S J Eustace
Journal:  Skeletal Radiol       Date:  2008-11-14       Impact factor: 2.199

View more
  1 in total

1.  Application of 18F-FDG PET-CT Images Based Radiomics in Identifying Vertebral Multiple Myeloma and Bone Metastases.

Authors:  Zhicheng Jin; Yongqing Wang; Yizhen Wang; Yangting Mao; Fang Zhang; Jing Yu
Journal:  Front Med (Lausanne)       Date:  2022-04-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.